Interesting response. Obviously I'm not privy to the full...

Interesting response. Obviously I'm not privy to the full exchange you've had.

However it would be nice if companies during clinical trials gave relevant information to the market. I find this a major failing in biotech - its so often sit and hope for extended periods of time. When drilling for oil, I get the rig on site, time estimates, notified of delays, and major issues. Its fairly consistent across the board. With biotech we range from reporting numbers enrolled to guessing games and silence. Let alone other issues.

So the 80+% reported previously. Is this now less due to drop out. If so how much. Why has this issue appeared to have leaked out to the market - I recall other posters mentioning issues with the trial. Was there an announcement. How does it affect their timelines. How does it affect cash flow?